Skip to content
Top Menu
  • Log In
  • Register
  • Facebook
  • Twitter
  • LinkedIn
MyChesCo

MyChesCo

Chester County News and Community Website

  • Communities
    • Avondale
    • Berwyn
    • Coatesville
    • Cochranville
    • Devon
    • Downingtown
    • Exton
    • Honey Brook
    • Kennett Square
    • Malvern
    • Oxford
    • Paoli
    • Parkesburg
    • Phoenixville
    • Spring City
    • Toughkenamon
    • West Chester
    • West Grove
  • Education
    • Chester County Intermediate Unit
    • School Districts
      • Avon Grove School District
      • Coatesville Area School District
      • Downingtown Area School District
      • Great Valley School District
      • Kennett Consolidated School District
      • Octorara Area School District
      • Owen J. Roberts School District
      • Oxford Area School District
      • Phoenixville Area School District
      • Spring-Ford Area School District
      • Tredyffrin-Easttown School District
      • Twin Valley School District
      • Unionville-Chadds Ford School District
      • West Chester Area School District
    • Charter Schools
    • Independent Schools
    • Colleges and Universities
    • Chester County Library System
  • News
    • Traffic
    • Weather
    • Business
    • Health / Medical
    • National
    • Pennsylvania
    • Sports
  • Entertainment
  • Lifestyle
  • Tools
    • Members
    • Groups
    • Submit an Article
    • Contact Us
    • Signup for Newsletter
    • Contests and Giveaways
    • Gas Prices
    • Register
    • Log In
  • About
    • MyChesCo
    • Writing for Us
    • Advertising with Us
    • Contacting Us
    • Citizen Journalism
    • Submitting Articles
    • Starting a Group
    • How to Support Us
    • Terms of Service
    • Privacy Policy
    • DMCA Policy
    • AI Disclosure
  • Shop

Clinical trials

Medical
Regional

Medicus Pharma Receives FDA Clearance to Begin Phase 2b Teverelix Study

February 16, 2026February 15, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate a Phase 2b dose-optimization trial …

Medicus Pharma Receives FDA Clearance to Begin Phase 2b Teverelix Study Read More

Medical research
Regional

Experimental Pompe Therapy Shows Early Promise in Trial

February 14, 2026February 13, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Aro Biotherapeutics reported interim data from a Phase 1b study of ABX1100, an investigational therapy for late-onset Pompe disease, showing the drug was generally well tolerated and …

Experimental Pompe Therapy Shows Early Promise in Trial Read More
Medical
Regional

FDA Clears Medicus to Advance Prostate Cancer Drug Aimed at Heart-Risk Patients

February 10, 2026February 10, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) has received clearance from the U.S. Food and Drug Administration to proceed with a Phase 2b clinical study of Teverelix, a long-acting …

FDA Clears Medicus to Advance Prostate Cancer Drug Aimed at Heart-Risk Patients Read More

Prelude Therapeutics
Regional

FDA Clears Prelude’s Experimental Cancer Drug, Opening New Path for Blood Disorders

February 8, 2026February 6, 2026 - by Timothy Alexander

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) said the U.S. Food and Drug Administration has cleared its investigational new drug application for PRT12396, allowing the company to begin a …

FDA Clears Prelude’s Experimental Cancer Drug, Opening New Path for Blood Disorders Read More
Frontage Laboratories
Business

Frontage Scales Global Phase I Reach as Patent Cliff Accelerates Drug Trials

February 5, 2026February 4, 2026 - by Timothy Alexander

EXTON, PA — Frontage Laboratories, Inc. announced a major expansion of its early phase clinical research capabilities across the United States and China, positioning the company to meet surging demand …

Frontage Scales Global Phase I Reach as Patent Cliff Accelerates Drug Trials Read More

Aprea Therapeutics
Regional / Research

Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial

February 3, 2026February 2, 2026 - by Timothy Alexander

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported its first unconfirmed partial response in a Phase 1 study of its experimental cancer drug APR-1051, an early signal the company …

Early Cancer Signal Emerges as Aprea Drug Shrinks Tumors in Phase 1 Trial Read More
Aclaris Therapeutics
Research

Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study

February 3, 2026February 2, 2026 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (Nasdaq: ACRS) reported striking preclinical results for its experimental oral drug ATI-2138, showing rapid, near-complete, and sustained hair regrowth in a severe mouse model …

Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study Read More

Traws Pharma
Regional

Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones

February 2, 2026February 2, 2026 - by Timothy Alexander

NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) said it has completed enrollment in a 90-patient Phase 2 study testing its experimental oral COVID-19 treatment ratutrelvir against PAXLOVID®, reporting early …

Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones Read More
Medical research
Regional

Experimental Pompe Therapy Shows Early Signal Ahead of Key San Diego Reveal

January 31, 2026January 30, 2026 - by Timothy Alexander

PHILADELPHIA, PA — Aro Biotherapeutics said it will present interim clinical data next month from its ongoing Phase 1b trial of ABX1100, an experimental therapy aimed at treating late-onset Pompe …

Experimental Pompe Therapy Shows Early Signal Ahead of Key San Diego Reveal Read More
Suvoda
Regional

Suvoda Bets on Merger, AI to Simplify Clinical Trials and Boost Growth

January 25, 2026January 24, 2026 - by Timothy Alexander

ONSHOHOCKEN, PA — Suvoda said it made significant strides in 2025 toward simplifying the clinical trial experience for patients and research sites, pointing to its merger with Greenphire, expanded product …

Suvoda Bets on Merger, AI to Simplify Clinical Trials and Boost Growth Read More

Posts pagination

Previous 1 … 6 7 8 … 37 Next

Trending News

  • Barricaded Wawa Standoff Erupts Into Fire and Taser Arrest

  • Radian to Outline Growth Strategy at June Investor Day

  • New Federal Student Loan Caps Could Shake Up Graduate Schools

  • Medicare to Cap Some GLP-1 Drug Costs at $50 for Seniors

  • HHS Pushes New Mental Health Rules Amid Medication Concerns

Subscribe for Updates

Follow Us

  • Facebook
  • X
  • LinkedIn
  • Google
  • RSS Feed

Tools

  • Members
  • Newsletter
  • Events
  • Groups
  • Guest Articles
  • Coupon Center
  • Gas Prices
  • Log In
  • Register

About Us

  • About MyChesCo
  • Advertise
  • Contact Us
  • Support Us
  • Write for Us
  • Terms of Service
  • Privacy Policy
  • DMCA Policy
  • Affiliate Disclaimer

Recommended Reading

Raul Zavala

Barricaded Wawa Standoff Erupts Into Fire and Taser Arrest

2 hours ago12 hours ago

Department of Veterans Affairs

VA Reports Record Suicide Screening, Follow-Up Rates

14 hours agoMay 10, 2026

PHL gamma-butyrolactone

CBP Seizes Liquid Ecstasy Precursor Shipped to Massachusetts

May 9, 2026May 9, 2026

Copyright © 2026 MyChesCo.